TY - JOUR PY - 2020/10/12 Y2 - 2024/03/29 TI - Stronger inhibitory effects of ticagrelor plus aspirin compared with clopidogrel plus aspirin on arachidonic acid induced platelet aggregation in patients with acute coronary syndrome with PCI JF - Journal of the Pakistan Medical Association JA - J Pak Med Assoc VL - 71 IS - 2 SE - Short Communication / Short Report DO - 10.47391/JPMA.029 UR - https://ojs.jpma.org.pk/index.php/public_html/article/view/783 SP - 540-542 AB - <h2><strong>Abstract</strong></h2><h2><strong>Antagonists of the adenosine diphosphate (ADP) receptor, P2Y12 may inhibit platelet aggregation resulting from stimulation with arachidonic acid (AA). The potent P2Y12 blocker, ticagrelor has greater anti-platelet effects than clopidogrel. We explored the effects of ticagrelor versus clopidogrel on mean maximum aggregation ratios (MAR%) in response to AA stimulation in patients receiving conventional aspirin dosages. A total of 613 acute coronary syndrome (ACS) patients were followed from October 2017 to October 2018. At the 1- and 6-month follow-up visit, mean AA-MAR% was lower in the ticagrelor group when compared with the clopidogrel group (28.9% vs. 31.7%, 28.4% vs. 31.0%, P&lt;0.001 and P=0.001, respectively). BARC1-2 bleeding occurred with greater frequency with ticagrelor rather than clopidogrel treated patients (29.3% vs. 9.5%, P&lt;0.001; 23.5% vs. 9.3%, P&lt;0.001). Excessive platelet inhibition and decreased AA-MAR% were considered the main reasons for the severe subcutaneous/dermal bleeding in ticagrelor treated patients.</strong></h2><h2>Continuous...</h2> ER -